Destiny Pharma

Clinical stage biotechnology company, Destiny Pharma, has announced that the US Food and Drug Administration (FDA) has accepted its investigational new drug application (IND) for its lead clinical drug candidate, XF-73. Read more


Destiny Pharma have announced the results of a US clinical trial of the new preventive anti-bacterial drug exeporfinium chloride. Read more


The O’Neill review into antimicrobial resistance (AMR) challenges governments, industry and the medical profession to get to grips with bacterial resistance to antibiotics, “one of the biggest health threats facing mankind” Read more